Search Results
HFA-ICOS Baseline Cardio-Oncology Risk Assessment for Anthracycline Chemotherapy
Stratifies cardiotoxicity risk in cancer patients scheduled to receive anthracycline-based chemotherapy.Anthracycline chemotherapy cardiotoxicity risk assessment.
HFA-ICOS Baseline Cardio-Oncology Risk Assessment for Multiple Myeloma Therapies
Stratifies cardiotoxicity risk in cancer patients scheduled to receive multiple myeloma therapies.Multiple myeloma therapy cardiotoxicity risk assessment.
HFA-ICOS Baseline Cardio-Oncology Risk Assessment for VEGF Inhibitors
Stratifies cardiotoxicity risk in cancer patients scheduled to receive VEGF inhibitor therapy.VEGF inhibitor cardiotoxicity risk assessment.
HFA-ICOS Baseline Cardio-Oncology Risk Assessment for HER2-Targeted Therapies
Stratifies cardiotoxicity risk in cancer patients scheduled to receive HER2-targeted therapies.HER2-targeted therapy cardiotoxicity risk assessment.
HFA-ICOS Baseline Cardio-Oncology Risk Assessment for Multi-Targeted Kinase Inhibitors for Chronic Myeloid Leukemia (CML)
Stratifies cardiotoxicity risk in CML cancer patients scheduled to receive BCR-ABL TKIs.BCR-ABL TKI therapy cardiotoxicity risk assessment.
HFA-ICOS Baseline Cardio-Oncology Risk Assessment for Combination Rapidly Accelerated Fibrosarcoma (RAF) and Mitogen-Activated Extracellular Signal-Regulated Kinase (MEK) Inhibitors
Stratifies cardiotoxicity risk in cancer patients scheduled to receive combination RAF and MEK inhibitors.RAF-MEK inhibitor cardiotoxicity risk assessment.
Contact us